Omacetaxine mepesuccinate - Teva Pharmaceutical Industries

Drug Profile

Omacetaxine mepesuccinate - Teva Pharmaceutical Industries

Alternative Names: C41443; Ceflatonin®; CGX-635; CXS-635; HHT; Homoharringtonine; Homoharringtonine-ChemGenex; NCI 141633; Omapro™; Synribo

Latest Information Update: 18 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemGenex Pharmaceuticals; Stragen Pharma SA
  • Developer ChemGenex Pharmaceuticals; Roswell Park Cancer Institute; Teva Pharmaceutical Industries; University of Hong Kong; University of Texas M. D. Anderson Cancer Center
  • Class Alkaloids; Antineoplastics; Harringtonines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin D1 inhibitors; MCL1 protein inhibitors; Protein synthesis inhibitors; Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Chronic myeloid leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Haematological malignancies
  • Discontinued Acute promyelocytic leukaemia; Solid tumours

Most Recent Events

  • 01 Jul 2018 Emory University and Teva Pharmaceuticals completes a phase II trial for Acute myeloid leukaemia in USA (NCT01873495)
  • 06 Jun 2018 Teva Pharmaceutical Industries terminates a phase I/II trial due to an inability to accrue additional sites and enrol an adequate number of participants for Chronic myeloid leukaemia (Second-line therapy or greater) in USA (SC) (NCT02078960)
  • 07 Jul 2017 Discontinued - Phase-I for Solid tumours (Second-line therapy or greater) in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top